Laurus Labs Ltd - 540222 - Business Responsibility and Sustainability Reporting (BRSR)
Pursuant to Regulation 34 of SEBI (LODR) Regulations, 2015, please find enclosed the Business Responsibility and Sustainability Report for FY 2022-23.21-06-2023
21-06-2023
Laurus Labs Ltd - 540222 - Notice Of 18Th AGM To Be Held On July 14, 2023 (IST)
Notice of 18th AGM to be held on July 14, 2023 (IST)21-06-2023
Laurus Labs Ltd - 540222 - Reg. 34 (1) Annual Report.
Pursuant to Regulation 34 of SEBI (LODR) Regulations, 2015, please find enclosed the Notice convening the 18th Annual General Meeting (AGM) of shareholders and the Annual Report for the financial year 2022-23 which will be circulated to the shareholders through electronic mode for the AGM to be held on Friday, July 14, 2023 at 03.00 PM (IST) through video conference (VC). The Notice and the annual report will also be made available on the Company's website at www.lauruslabs.com.21-06-2023
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations'), the details of Analyst/Institutional Investor meeting scheduled on June 20, 2023 with CEO/promoter day - JM Financial in person.20-06-2023
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Laurus labs has signed an MOA with IIT Kanpur (IITK) to bring novel gene therapy assets to market. As per MOA, Laurus labs will in-license few gene therapy assets and will provide research grant for advancing these products through the pre-clinical development. Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets. Additionally, Laurus labs will establish a GMP facility at the Techno Park facility of IITK. Department of Biological Sciences and Bioengineering (BSBE) at IIT Kanpur has been working on gene therapy for the last few years and have developed few gene therapy assets along with technology for novel Adeno Associated Virus (AAV) vectors. They have filed IPs around these products and few additional patent applications will be filed in due course.19-06-2023
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed the newspaper advertisement regarding the 18th Annual General Meeting of the Company to be held through Video Conferencing (VC) and proposed dispatch of Notice and Annual Report through electronic mode as per the circulars issued by the Regulatory Authorities. The Advertisement appeared in the Business Standard (English Newspaper) and Prajasakthi (Telugu Newspaper) on June 16, 2023. The same is also available on the Company's website at www.lauruslabs.com.16-06-2023
Laurus Labs Ltd - 540222 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Further to our intimation dated February 10, 2023, on the Inspection conducted by the United States Food & Drug Administration (USFDA) at our formulations manufacturing facility Unit-2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh from 6th February, 2023 to 10th February, 2023, we wish to inform you that the Company has received the Establishment Inspection Report (EIR) from USFDA. This is for your information and record.15-06-2023
Buy or sell: Vaishali Parekh recommends three stocks to buy today 5th June
Buy or sell stocks: Vaishali Parekh has recommended three stocks to buy today Laurus Labs, Mazagon Dock, Jindal Steel05-06-2023
Laurus Labs shares rise 3% after upping stake in gene therapy company
The company has signed definitive agreements to acquire additional stake of 7.24% in Immunoadoptive Cell Therapy Private Limited (lmmunoACT) for a cash consideration of Rs 80 crore.01-06-2023
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed the Press Release titled - 'Laurus Labs further invests in Cell and Gene therapy company ImmunoACT; to hold 33.86% stake post- completion of the transaction'. This is for your information and records31-05-2023